Innovent Biologics, Inc. (1801.HK) HKSE

87.05

-1.65(-1.86%)

Updated at May 13 04:08PM

Currency In HKD

Key Executives

Name	Title	Pay	Year Born
De-Chao Yu	Co-Founder, Chairman & Chief Executive Officer	49.22M	1964
Qian Zhang	Chief Commercial Officer, General Manager & Executive Director	4.86M	1988
Hao Xi Ede	Executive Director & Fund Managing Partner	8.04M	1959
Min Liu	Chief Commercial Officer	0	1973
Kaisong Zhou	Chief Operating Officer	0	N/A
Raj Dhodda	Senior Vice President	0	N/A
Samuel Suhua Zhang	Global Chief Business Officer	0	1968
Blake Salisbury	Senior Vice President	0	N/A
Zhengwei Song	Director of IR & Financial Strategy	0	N/A
Hui Zhou	Chief R&D Officer for Oncology	0	N/A
Cong Ding	General Counsel	0	N/A
Fei You	Chief Financial Officer	0	1979

Name

Title

Pay

Year Born

De-Chao Yu

Co-Founder, Chairman & Chief Executive Officer

49.22M

1964

Qian Zhang

Chief Commercial Officer, General Manager & Executive Director

4.86M

1988

Hao Xi Ede

Executive Director & Fund Managing Partner

8.04M

1959

Min Liu

Chief Commercial Officer

1973

Kaisong Zhou

Chief Operating Officer

N/A

Raj Dhodda

Senior Vice President

N/A

Samuel Suhua Zhang

Global Chief Business Officer

1968

Blake Salisbury

Senior Vice President

N/A

Zhengwei Song

Director of IR & Financial Strategy

N/A

Hui Zhou

Chief R&D Officer for Oncology

N/A

Cong Ding

General Counsel

N/A

Fei You

Chief Financial Officer

1979

Description

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.